Privia Health Group, Inc.
PRVA Healthcare Health Information Services
Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024.
- Revenue
- +13.2%
- EPS
- +83.3%
- Free cash flow
- −44.4%
Quarter to September 2026, against a year earlier
Follow PRVA
Alert me
Privia Health Group, Inc. (PRVA) P/S ratio
As of 5 November 2026, Privia Health Group, Inc. (PRVA) trades at a P/S ratio of 1.2×. Over the past ten years it has ranged from 1.0× (September 2026) to 5.8× (June 2021); the current reading is higher than 11% of that period. That is below the Health Information Services industry median of 1.8× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 1.4× | 1.50% |
| FY2024 | 1.3× | (19.48%) |
| FY2023 | 1.7× | (8.20%) |
| FY2022 | 1.8× | (34.02%) |
| FY2021 | 2.8× | 2.10% |
| FY2020 | 2.7× | 0.00% |
| FY2019 | 2.7× | 0.00% |
| FY2018 | 2.7× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 1.0× | (25.05%) |
| Jun 2026 | 1.4× | 21.06% |
| Mar 2026 | 1.1× | (16.69%) |
| Dec 2025 | 1.4× | (8.82%) |
| 23 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| TDOC Teladoc Health, Inc. compare | 0.7× |
| PRVA Privia Health Group, Inc. | 1.2× |
| OMCL Omnicell, Inc. compare | 1.4× |
| GDRX GoodRx Holdings, Inc. compare | 1.5× |
| WAY Waystar Holding Corp. compare | 4.4× |
| CERT Certara, Inc. compare | 4.7× |
| SDGR Schrodinger, Inc. compare | 8.1× |
| DOCS Doximity, Inc. compare | 9.0× |
| HTFL Heartflow, Inc. compare | 21.3× |
| Health Information Services industry median | 1.8× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on PRVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement